0001660334-26-000008
SEC filingVerrica Pharmaceuticals Inc. reported a net loss of $17.9 million for fiscal year 2025, an improvement from a $76.6 million loss in 2024. Total revenue grew significantly to $35.6 million, driven by $15.3 million in product revenue from YCANTH (VP-102) and $20.3 million in license and collaboration revenue, primarily from milestone payments from Torii. Operating expenses totaled $47.8 million, with selling, general and administrative costs of $35.2 million and research and development expenses of $8.9 million. The company ended the year with $30.1 million in cash and cash equivalents, a decrease of $16.2 million from the prior year, and an accumulated deficit of $324.9 million. The financial statements include a going concern qualification, indicating substantial doubt about the company's ability to continue as a going concern within one year.
Verrica Pharmaceuticals reported fiscal year 2025 results showing significant revenue growth but continued operating losses. Total revenue reached $35.6 million, a substantial increase from $7.6 million in 2024. This growth was primarily driven by $20.3 million in license and collaboration revenue from Torii Pharmaceutical, including milestone payments of $8.0 million in July 2025 and $10.0 million in September 2025. Product revenue from YCANTH (VP-102) contributed $15.3 million. Despite the revenue increase, the company reported a net loss of $17.9 million, which represents a significant improvement from the $76.6 million loss in 2024. Operating expenses totaled $47.8 million, with selling, general and administrative expenses of $35.2 million and research and development expenses of $8.9 million.
The company's revenue consists of two primary components: product revenue and license/collaboration revenue. Product revenue, net of $15.3 million represents sales of YCANTH (VP-102) for the treatment of molluscum contagiosum. License and collaboration revenue of $20.3 million primarily comes from the Torii Agreement, including milestone payments triggered by regulatory achievements in Japan and clinical development progress. The company reached approximately 250 million covered lives in the United States through positive insurance payor coverage decisions for YCANTH. Geographic revenue breakdown beyond the U.S. and Japan partnerships is not specifically quantified in the filing.
Gross margin improved significantly to 90.3% in 2025 from 75.5% in 2024, reflecting the mix shift toward higher-margin license revenue and improved product economics. Cost of product revenue was $2.2 million, representing 14.4% of product sales. The company continues to operate at a loss with an operating loss of $12.2 million, though this represents substantial improvement from the $65.9 million operating loss in 2024. Selling, general and administrative expenses decreased to $35.2 million from $58.8 million in the prior year, while research and development expenses decreased to $8.9 million from $11.8 million.
The company used $17.6 million in cash from operating activities during 2025. Cash and cash equivalents decreased to $30.1 million from $46.3 million at the end of 2024. Total assets were $47.1 million, with current assets of $42.5 million including $5.3 million in accounts receivable. Total liabilities were $22.4 million, resulting in stockholders' deficit equity of $24.7 million. The company extinguished all outstanding debt obligations of $35.0 million in November 2025, recognizing a $1.5 million loss on extinguishment. The balance sheet shows an accumulated deficit of $324.9 million.
The financial statements include a going concern qualification, indicating substantial doubt about the company's ability to continue as a going concern within one year after the financial statements are issued. Management plans to secure additional capital through equity or debt financings, partnerships, or other sources to fund planned commercial and development activities. The company continues development of YCANTH for common warts (Phase 3 program initiated in December 2025) and VP-315 for basal cell carcinoma (planning Phase 3 program). The company may pursue non-dilutive strategic partnerships to help fund development and commercialization. Key risk factors include the need for additional financing, clinical development risks, and competition in dermatology therapeutics.